Timothy Scannell appointed to the Board
("Renalytix" or the "Company")
Confirmation of Appointment of
As an accomplished leader in healthcare innovation,
For further information, please contact:
|
|||
|
Via Walbrook PR |
||
|
|
||
Stifel (Nominated Adviser, Joint Broker) |
Tel: 020 7710 7600 |
||
|
|
||
|
|
||
|
Tel: 020 7597 4000 |
||
|
|
||
|
|
||
|
Tel: 020 7933 8780 or renalytix@walbrookpr.com |
||
|
Mob: 07980 541 893 / 07584 391 303 / 07407 804 654 |
||
|
|
||
|
Tel: 415-389-6400 or investors@renalytix.com |
||
|
|
||
|
|
|
|
AIM Rule Regulatory Disclosures
In accordance with Schedule 2(g) of the AIM Rules,
Current |
Past 5 years |
Insulet Corporation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fulcrom, Corp. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Novadaq Technologies ULC |
|
|
|
|
|
|
|
|
|
Physio-Control, |
|
|
|
|
|
|
|
|
|
|
|
Stryker Canada Operations ULC |
|
|
|
|
|
|
|
|
|
|
|
|
Save for the disclosures above, there are no further disclosures to be made in accordance with AIM Rule 17 and Schedule 2(g) of the AIM Rules.
About Kidney Disease
Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The
About Renalytix
About KidneyIntelX
KidneyIntelX, is a first-of-kind solution that enables early-stage diabetic kidney diseases (DKD) progression risk assessment by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record, or EHR, systems, and employs a proprietary algorithm to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in CKD, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk
Sources
1 https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html
2 https://www.nicresearch.com/clinical-research-necessary-nephrology/
3 https://optn.transplant.hrsa.gov/
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning: the potential benefits, including economic savings, of KidneyIntelX, the potential for KidneyIntelX to receive regulatory approval from the FDA, the commercial prospects of KidneyIntelX, if approved, including whether KidneyIntelX will be successfully adopted by physicians and distributed and marketed, our expectations regarding reimbursement decisions and the ability of KidneyIntelX to curtail costs of chronic and end-stage kidney disease, optimize care delivery and improve patient outcomes. Words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "seeks," and similar expressions are intended to identify forward-looking statements. We may not actually achieve the plans and objectives disclosed in the forward-looking statements, and you should not place undue reliance on our forward-looking statements. Any forward-looking statements are based on management's current views and assumptions and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, among others: that KidneyIntelX is based on novel artificial intelligence technologies that are rapidly evolving and potential acceptance, utility and clinical practice remains uncertain; we have only recently commercially launched KidneyIntelX; and risks relating to the impact on our business of the COVID-19 pandemic or similar public health crises. These and other risks are described more fully in our filings with the
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the